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Summary  Cortisol  is  a  key  regulator  of  the  immune  system,  energy  metabolism,  and  stress,
yet its  relevance  to  fatigue  experienced  by  people  with  relapsing-remitting  multiple  sclerosis
(RRMS) remains  uncertain.  We  examined  cortisol  secretory  activity  in  RRMS  and  its  associ-
ation with  fatigue  severity  between-individuals  and  within-individuals  (day-to-day)  using  a
case—control  ecological  momentary  assessment  design.  While  undergoing  usual  daily  routines,
38 people  with  RRMS  and  38  healthy  control  participants  provided  saliva  samples  at  strategic
time-points  over  4  consecutive  weekdays  to  measure  the  cortisol  awakening  response  (CAR;  0,
30, and  45  min  after  awakening)  and  the  diurnal  cortisol  slope  (DCS;  6  quasi-random  samples
provided between  1000  h  and  2000  h).  Recalled  fatigue  was  measured  at  baseline,  and  daily
fatigue was  measured  as  the  mean  average  of  momentary  fatigue  ratings  provided  alongside
each DCS  sample.  Multilevel  modeling  found  CAR  output  was  greater  in  RRMS  than  controls,
and recalled  fatigue  in  RRMS  was  associated  with  both  lower  waking  cortisol  level  and  larger
awakening  response.  Day-to-day,  the  CAR  was  not  associated  with  same-day  fatigue  levels  in
RRMS. Cortisol  appears  to  have  a  role  in  fatigue  experienced  in  RRMS,  but  whether  it  is  a  causal
factor remains  unclear.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC  BY
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. Introduction
ultiple  sclerosis  (MS)  is  a  disease  characterized  by
utoimmune-mediated  inﬂammatory  demyelination  and
eurodegeneration  (Compston  and  Coles,  2008).  Fatigue  is
requently  described  as  one  of  the  most  common  and  dis-
bling  symptoms  in  MS,  affecting  60—85%  of  people  with  MS
n access article under the CC BY license (http://creativecommons.
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(Lerdal  et  al.,  2003;  Minden  et  al.,  2006).  Current  under-
standing  of  the  etiology  of  MS  fatigue  is  uncertain,  with  many
disease-mediated  mechanisms  and  secondary  factors  such
as  depression  and  sleep  dysfunction  potentially  implicated
(Induruwa  et  al.,  2012).
With  no  licensed  treatment  for  MS  fatigue,  robust
information  about  the  underlying  mechanisms  of  fatigue
experience  is  required  in  order  to  identify  potential  tar-
gets  for  intervention.  There  are  several  mechanisms  by
which  cortisol,  the  adrenal  product  of  the  hypothalamic—
pituitary—adrenal  (HPA)  axis,  may  be  relevant  to  MS  fatigue:
(1)  cortisol  is  generally  considered  the  primary  endogenous
regulator  of  immune  inﬂammation  (Chrousos,  1995);  (2)  cor-
tisol  is  an  important  regulator  of  energy  metabolism  via
glycogenesis  promotion  (Sapolsky  et  al.,  2000);  and  (3)  while
several  reviews  highlight  a  positive  association  between
stressful  experience  and  risk  of  MS  symptom  exacerbation
(Mohr  et  al.,  2004;  Artemiadis  et  al.,  2011),  cortisol  is  fun-
damental  within  the  stress  response  (Dickerson  and  Kemeny,
2004).  Hypocortisolism  is  commonly  reported  in  chronic
fatigue  syndrome  (Papadopoulos  and  Cleare,  2012)  but  the
importance  of  HPA  axis  (dys)function  to  fatigue  experienced
by  individuals  with  other  chronic  conditions  has  received
relatively  little  attention  (Powell  et  al.,  2013).  Our  under-
standing  of  unstimulated  cortisol  secretory  activity  in  MS
and  its  relevance  to  MS  fatigue  is  limited,  particularly  in
daily  life.
1.1.  The  HPA  axis  in  MS
HPA  axis  non-suppression  by  dexamethasone  appears  most
prevalent  in  disease-active  MS,  such  as  in  relapse-phase
relapsing-remitting  MS  (RRMS)  and  progressive  MS-types
(Ysrraelit  et  al.,  2008).  HPA  axis  hyper-reactivity  to  CRH
stimulation  has  been  reported  in  MS  (e.g.,  Fassbender  et  al.,
1998)  but  studies  describe  both  positive  and  negative  associ-
ations  between  Dex/CRH  test  (Heuser  et  al.,  1994)  outcomes
and  gadolinium-enhancing  lesions  on  MRI  (Fassbender  et  al.,
1998;  Schumann  et  al.,  2002):  an  important  marker  of
inﬂammatory  disease  activity.
Greater  24  h  urinary  cortisol  outputs  have  been  reported
in  people  with  MS  compared  with  healthy  controls  (Ysrraelit
et  al.,  2008)  but  24  h  urinary  cortisol  observations  provide
little  information  regarding  cortisol  circadian  rhythm
dynamics.  More  recently,  2-day  salivary  cortisol  studies  have
compared  facets  of  the  cortisol  circadian  rhythm  in  people
with  MS  and  healthy  controls  (Gold  et  al.,  2010;  Kern  et  al.,
2011,  2013).  Hyper-secretion  of  cortisol  has  been  reported
within  the  cortisol  awakening  response  (CAR)  (Kern  et  al.,
2011,  2013)  and  in  the  evening  (Gold  et  al.,  2010)  in  people
with  RRMS.
Depressive  symptomatology  may  underlie  HPA  axis  hyper-
activity  in  MS,  with  HPA  axis  hyperactivity  a  relatively
consistent  biological  marker  in  major  depressive  disorder
(Pariante  and  Lightman,  2008).  Several  studies  have  pro-
vided  empirical  support  for  this  hypothesis  in  MS,  but
ﬁndings  remain  mixed.  Gold  et  al.  (2010)  observed  that
people  with  RRMS  and  high  levels  of  depressive  symptoms
had  ﬂatter  diurnal  cortisol  slopes  (DCS)  and  higher  evening
cortisol  levels  than  people  with  RRMS  and  low  depressive
symptom  scores.  In  a  later  study,  the  same  research  group
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eported  ﬂatter  DCS  and  greater  daily  cortisol  output  in
ndividuals  with  RRMS  and  a  clinical  diagnosis  of  major
epressive  disorder  compared  to  individuals  with  RRMS  but
ithout  comorbidity  (Gold  et  al.,  2011).  A  further  study  in
RMS  found  CARs  were  larger  in  a group  with  more  depres-
ive  symptoms  (Kern  et  al.,  2011).  However,  most  recently,
ern  et  al.  (2013)  found  no  association  between  depressive
ymptoms  and  the  CAR  in  either  RRMS  or  secondary  progres-
ive  MS.
.2.  HPA  axis  activity  and  MS  fatigue
urrent  evidence  suggests  reduced  dynamic  cortisol  vari-
bility  is  more  relevant  to  fatigue  experience  than  lower
ortisol  outputs,  per  se  (Powell  et  al.,  2013).  Gold  et  al.
2011)  remains  the  only  study  to  examine  associations
etween  salivary  cortisol  and  MS  fatigue,  reporting  no  asso-
iation  between  fatigue  and  either  the  CAR  or  DCS  in  a
RMS  sample  where  nearly  a  quarter  also  had  major  depres-
ive  disorder.  Given  that  fatigue  is  a  common  symptom  in
epression  (American  Psychiatric  Association,  2000),  the
ole  of  cortisol  in  the  severity  of  MS-related  fatigue  remains
nclear.
Several  qualitative  studies  have  indicated  that  individ-
als  describe  very  different  levels  of  symptom  intensity
rom  day  to  day  (e.g.,  Mills  and  Young,  2008).  However,
ery  little  research  has  sought  to  understand  within-person
ariability  in  fatigue  severity  in  any  population.  There  is  a
rowing  literature  proposing  that  state  variation  in  the  CAR
s  implicated  in  same-day  experience  (Powell  and  Schlotz,
012;  Law  et  al.,  2013).  Small  yet  statistically  signiﬁcant
ithin-person  associations  have  been  reported  between
maller  CARs  and  greater  levels  of  same-day  exhaustion
n  individuals  with  burnout  (Sonnenschein  et  al.,  2007),
hile  two  studies  have  described  within-person  associ-
tions  between  low  morning  cortisol  and  greater  levels
f  same-day  physical  symptoms  in  non-clinical  popula-
ions  (Adam  et  al.,  2006;  Gartland  et  al.,  2014).  The  role
f  the  CAR  in  daily  fatigue  experience  in  MS  warrants
nvestigation.
.3.  Aims
his  daily  life  study  aimed  to  explore  the  relationship
etween  cortisol  and  fatigue  severity  in  RRMS  while
ddressing  several  limitations  of  previous  studies,  which
ave  used  relatively  short  2-day  saliva-sampling  proto-
ols  with  unmonitored  compliance,  and  often  included
articipants  with  comorbidities.  There  were  two  primary
bjectives:  First,  to  comprehensively  explore  two  facets
f  the  cortisol  circadian  rhythm  (CAR  and  DCS)  in  a  RRMS
roup  without  multi-morbidity;  and  second,  to  examine
ssociations  between  cortisol  secretory  activity  and  fatigue
everity  in  RRMS.  The  following  hypotheses  were  tested  in
 case—control  design:  (1)  the  CAR  is  larger  and  DCS  is  ﬂat-
er  in  people  with  RRMS  compared  to  healthy  individuals,
ndependent  of  depressive  symptoms  and  chronic  stress;  (2)
atigue  severity  is  associated  with  an  attenuated  CAR  and  a
atter  DCS  in  both  groups;  (3)  within  individuals,  attenua-
ions  in  CAR  are  associated  with  greater  same-day  fatigue
everity  in  both  groups.
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more  anxiety  and  depression  symptoms.  The  internal  con-22  
. Materials and methods
thical  approval  was  granted  by  the  UK  NHS  National
esearch  Ethics  Service  Committee  (11/SC/0333)  and  Uni-
ersity  of  Southampton  Psychology  Ethics  Committee  (589).
ll  data  were  anonymized  before  analysis,  and  written
nformed  consent  was  provided  by  all  participants.
.1.  Participants
e  recruited  42  people  with  clinically  deﬁnite  RRMS  (Polman
t  al.,  2011),  and  40  age-  and  sex-matched  healthy  indi-
iduals.  The  RRMS  group  was  recruited  between  February
012  and  February  2013  from  consecutive  attendants  at
eurologist  and  specialist-nurse  clinics  at  University  Hos-
ital  Southampton  NHS  Foundation  Trust  and  Guy’s  and  St
homas’  NHS  Foundation  Trust,  and  from  UK  MS  Society  post-
ngs  in  Hampshire  and  Greater  London.  Of  those  individuals
pproached  to  be  part  of  the  RRMS  group,  37.1%  (76/205)
et  all  eligibility  criteria,  and  55.3%  (42/76)  went  on  to
nroll  and  participate  in  the  study.  Control  participants  were
ecruited  via  newspaper  and  University  intranet  postings.  All
articipants  were  of  working  age  (18—65  years),  and  ﬂuent
n  the  English  language.
The  RRMS  group  had  several  exclusion  criteria:  a clinical
elapse  and/or  corticosteroid  treatment  within  3  months;
nability  to  ambulate  300  m  without  rest  with/without
se  of  a  walking  aid;  a  diagnosed  physical  or  psychi-
tric  comorbidity;  a  Hospital  Anxiety  and  Depression  Scale
Zigmond  and  Snaith,  1983)  depression  subscale  score  ≥8,
ndicative  of  moderate  depression;  current  antidepressant
edication  use;  pregnancy;  care-giving;  and  shift-working.
urrent  use  of  a  disease  modifying  therapy  (DMT)  was
ermitted.  The  control  group  had  the  following  exclusion
riteria:  an  acute  or  chronic  disease  or  illness;  current
se  of  prescribed  medication;  pregnancy;  care-giving;  and
hift-working.
Within  the  RRMS  group,  one  participant  withdrew  citing
ncompatibility  of  the  study  protocol  alongside  their  job,
ne  withdrew  due  to  non-MS  related  illness,  and  two  partic-
pants’  data  were  lost  due  to  technical  faults.  Within  the
ontrol  group,  two  participants  were  later  excluded  due
o  consistent  extreme  and  outlying  salivary  cortisol  levels
ndicative  of  endocrine  abnormality.  This  redundancy  left  38
ell-matched  individuals  in  each  group.  Participant  charac-
eristics  are  presented  in  Table  1.
.2.  Study  procedure
he  study  implemented  an  ecological  momentary  assess-
ent  (EMA)  design,  measuring  salivary  cortisol  and  real-time
ssessments  of  fatigue  severity  with  high  ecological  validity
nd  limited  recall  bias  (Stone  and  Shiffman,  1994;  Schlotz,
012).  All  participants  began  by  attended  one-to-one  intro-
uctory  sessions  at  the  University  of  Southampton  or
nstitute  of  Psychiatry,  Kings  College  London.  All  participants
ompleted  baseline  questionnaires  and  were  given  Daily  Life
ssessment  packs  containing  36  pre-labeled  synthetic  Cor-
isol  Salivettes  (Sarstedt,  Leicester,  UK),  a  pre-programmed
lectronic  handheld  device  (Hewlett  Packard  iPAQ  111  Clas-
ic  Handheld,  Bracknell,  UK)  for  prompting  and  guiding  the
s
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MA  schedule,  and  a  reference  information  booklet.  Partic-
pants  were  given  training  in  how  to  provide  samples  and
perate  the  handheld  device,  and  left  once  conﬁdent  in
oing  so.
.3.  Baseline  self-report  measures
atigue  severity  was  measured  in  both  groups  by  the  Fatigue
cale  (FS;  Chalder  et  al.,  1993).  The  11-item  FS  meas-
res  fatigue  severity  over  the  last  month,  with  subscales
xamining  physical  fatigue  (7  items)  and  mental  fatigue  (4
tems).  Response  is  via  4-point  Likert  scale.  The  FS  was  used
ith  both  continuous  (range:  0—33)  and  bimodal  (range:
—11)  scoring  systems,  with  higher  scores  indicating  greater
atigue  severity.  FS  subscales  showed  excellent  internal  con-
istencies  within  the  present  study  (physical  fatigue,  ˛  =  .93;
ental  fatigue,  ˛  =  .85).  The  bimodal  scoring  system  distin-
uishes  between  severe  fatigue  and  normal  fatigue  by  a  ≥
 cut-off  (Chalder  et  al.,  1993):  a  cut-off  with  sensitivity  of
5.5%  and  speciﬁcity  of  74.5%  based  on  the  fatigue  item  of
he  Clinical  Interview  Schedule  (Lewis  et  al.,  1992).  We  use
his  cut-off  to  identify  individuals  with  clinically  signiﬁcant
atigue  in  secondary  analysis.  We  chose  the  FS  rather  than
he  Fatigue  Severity  Scale  (FSS;  Krupp  et  al.,  1989)  or  Mod-
ﬁed  Fatigue  Impact  Scale  (MFIS;  Multiple  Sclerosis  Council
or  Clinical  Practice  Guidelines,  1998) as  our  study  focussed
n  fatigue  severity,  and  neither  the  FSS  nor  the  MFIS  measure
he  concept  of  severity  directly:  both  measure  the  impact
f  fatigue  in  daily  life,  while  the  FSS  also  contains  items
ssessing  determinants  of  fatigue.  The  FS  has  been  used  in
everal  MS  studies  (e.g.,  Skerrett  and  Moss-Morris,  2006).
Neurological  disability  was  measured  in  the  RRMS  group
y  the  self-administered  Expanded  Disability  Status  Scale
EDSS-sa;  Bowen  et  al.,  2001).  Respondents  evaluated  a
eries  of  items  regarding  functioning  and  symptoms  ‘on  an
verage  day,  at  your  best’.  The  EDSS-sa  has  a  bespoke  rating
ystem  for  each  item,  contributing  to  an  overall  score  ran-
ing  from  0.0  (no  neurological  impairment)  to  10.0  (death
rom  MS).  The  EDSS-sa  is  highly  correlated  (r  =  .89)  with  the
riginal  physician-delivered  EDSS  (Kurtzke,  1983).
All  participants  completed  the  12-item  Chronic  Stress
creening  Scale  (CSSS).  The  CSSS  is  a  brief  summary  mea-
ure  of  chronic  stress  over  the  prior  3  months  derived  from
he  Trier  Inventory  of  Chronic  Stress  (Schulz  et  al.,  2004).
esponses  to  the  CSSS  are  on  a 0—4  rating  scale,  with  higher
cores  indicating  greater  experience  of  chronic  stress.  The
SSS  had  excellent  internal  consistency  in  the  present
tudy  (˛  =  .91).  The  CSSS  deﬁnes  an  individual  as  chronically
tressed  if  they  are  worrying  a  lot,  feeling  overextended
nd  overwhelmed,  and  receiving  no  recognition  for  their
fforts.
The  14-item  Hospital  Anxiety  and  Depression  Scale
HADS;  Zigmond  and  Snaith,  1983)  was  also  completed  by
ll  participants  to  measure  anxiety  and  depression  symp-
oms  over  the  last  week  on  a  0—3  rating  scale  (maximum
core  of  21  for  each  subscale),  with  higher  scores  indicatingistencies  for  the  HADS  subscales  were  excellent  for  anxiety
ymptoms  (˛  =  .85)  and  adequate  for  depressive  symptoms
˛  =  .65).  The  HADS  does  not  incorporate  items  regarding
omatic  symptoms  of  anxiety  or  depression,  such  as  fatigue.
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Table  1  Demographic  and  clinical  characteristics  of  study  participants.
RRMS  Control  p
N  38  38
Age 41.89  (7.53)
[28—54]
40.34  (8.16)
[27—56]
Gender (female/male)  31/7  31/7
Employment
Paid employment  30  33
Unpaid  employment  3  1
Unemployed  5  4
EDSS-sa  4.35  (1.40)
[0.00—6.00]
Years  since  diagnosis  6.03  (5.18)
[0—20]
Disease  modifying  therapy
Interferon  12
Glatiramer  acetate  6
Natalizumab  5
No DMT  15
Fatigue
FS 17.58  (7.09)
[1—32]
11.55  (2.87)
[4—21]
<.001
FS (physical  subscale)  11.18  (4.89)
[0—20]
7.26  (2.34)
[2—16]
<.001
FS (mental  subscale) 6.39  (2.66)
[1—12]
4.29  (0.96)
[2—7]
<.001
Stress
CSSS 19.82  (9.36)
[0—37]
14.11  (7.93)
[1—28]
.006
Anxiety and  depression
HADS-anxiety  7.50  (3.90)
[2—17]
4.82  (3.12)
[0—12]
.003
HADS-depression  4.00  (2.29)
[0—7]
2.08  (2.27)
[0—7]
<.001
Sleep quality  (person-mean)  6.07  (1.57)
[2.75—8.75]
6.22  (1.97)
[2.50—9.25]
.720
Sleeping hours  (person-mean)  7.83  (1.00)
[5.82—10.15]
7.63  (0.89)
[4.75—10.24]
.348
Note. Mean, standard deviation (), and range [] presented for all continuous variables. EDSS-sa indicates self-assessed Expanded Disability
Status Scale; DMT, disease modifying therapy; FS, Fatigue Scale; CSSS, Chronic Stress Screening Scale; HADS, Hospital Anxiety and
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2.4.  Ecological  momentary  assessment  schedule
The  EMA  schedule  was  carried  out  over  4  consecutive
weekdays,  guided  by  handheld  device  auditory  prompts,
as  participants  undertook  their  usual  daily  routines.  The
daily  EMA  schedule  was  composed  of  two  designs:  an  event-
based  ﬁxed  occasion  design  for  assessments  soon  after
awakening,  and  a  time-based  variable  occasion  design  with
stratiﬁed  random  sampling  for  assessments  later  in  the  day
(cf.  Schlotz,  2012).  The  event-based  design  incorporated
prompts  at  awakening  (S1  assessment),  30  min  after  awak-
ening  (S2),  and  45  min  after  awakening  (S3).  S1  assessment
time  was  deﬁned  as  the  time  of  a  pre-set  waking  alarm  that
could  be  no  later  than  0830  h,  or  the  time  of  manual  engage-
ment  with  the  handheld  if  waking  earlier  than  expected.
The  time-based  design  consisted  of  six  prompts  (S4—S9)
t
c
e
2istributed  between  1000  h  and  2000  h  by  an  algorithm  that
uasi-randomly  allocated  each  prompt  within  one  of  the  six
onsecutive  100  min  periods,  while  ensuring  no  two  prompts
ould  be  within  30  min.  To  minimize  missed  assessments,
articipants  could  postpone  any  S4—S9  assessment  for  5,  10,
r  15  min.
.4.1.  Cortisol  measurement
ine  saliva  samples  were  collected  per  day  for  the  analysis  of
ree  cortisol  content:  samples  at  S1—S3  measured  the  CAR;
amples  at  S4—S9  measured  the  DCS.  Upon  each  prompt,
he  handheld  brieﬂy  presented  a  3-digit  code  which  par-
icipants  recorded  on  the  salivette  used,  with  incorrectly
oded  salivettes  later  discarded  as  non-compliant  (Stetler
t  al.,  2004).  The  compliance  rate  here  was  92.0%,  with
518  usable  samples  from  a  possible  2736.
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During  the  CAR  measurement  period  (S1—S3),  partici-
ants  were  instructed  not  to  eat,  drink  anything  other  than
ater,  smoke,  brush  their  teeth,  or  exercise.  Throughout
he  rest  of  the  day,  there  were  no  behavioral  instructions
rior  to  saliva  sampling  but  potential  confounders  (eating,
rinking  coffee,  smoking,  physical  exertion,  sleeping)  were
onitored  by  handheld  self-reports.  We  used  samples  pro-
ided  at  S1—S3  to  compute  three  different  facets  of  the  CAR:
1)  the  area  under  the  curve  ground  (AUCg);  (2)  the  waking
ortisol  level  (S1);  and  (3)  the  area  under  the  curve  increase
AUCi);  (Pruessner  et  al.,  2003;  Fekedulegn  et  al.,  2007).
ere,  AUCg  measured  estimated  total  cortisol  output  in  the
5  min  after  awakening,  S1  cortisol  level  assessed  the  end
f  the  pre-awakening  cortisol  rise,  while  AUCi  measured  the
ynamic  change  in  cortisol  post-awakening.  Pre-awakening
s  thought  to  be  characterized  by  reduced  adrenal  sensitiv-
ty  to  ACTH  (Born  et  al.,  1999;  Hellhammer  et  al.,  2009;
low  et  al.,  2010),  but  post-awakening  is  characterized  by
eightened  adrenal  sensitivity  to  ACTH,  mediated  by  light-
ensitivity  (Thorn  et  al.,  2004;  Clow  et  al.,  2010).  A  previous
ystematic  review  suggested  attenuated  measures  of  diurnal
ortisol  variability,  including  CAR  AUCi,  are  more  relevant  to
atigue  than  measures  of  output  such  as  CAR  AUCg  (Powell
t  al.,  2013).
Participants  stored  used  salivettes  in  their  own  refriger-
tors  until  returning  them  to  the  lab  at  the  end  of  the  EMA
chedule,  where  they  were  frozen  at  −20 ◦C  until  assay.  Sam-
les  were  sent  in  one  batch  to  the  Biochemical  Laboratory
t  the  Division  of  Theoretical  and  Clinical  Psychobiology,
niversity  of  Trier,  Germany,  where  analysis  for  free  cor-
isol  content  (nmol/L)  was  by  time-resolved  immunoassay
ith  ﬂuorescent  detection  (Dressendörfer  et  al.,  1992).  The
etection  limit  for  the  assay  was  0.173  nmol/L.  Each  sample
as  measured  in  duplicate,  with  an  intra-assay  coefﬁcient  of
ariance  between  4.0%  and  6.7%,  and  inter-assay  coefﬁcient
f  variance  between  7.1%  and  9.0%.
.4.2.  Momentary  self-report  assessments
omentary  fatigue  was  measured  at  each  quasi-random
ssessment  (S4—S9)  with  a  single-item  developed  from  the
rief  Fatigue  Inventory  (Mendoza  et  al.,  1999):  ‘How  much
atigue  (tiredness,  weariness,  problems  thinking  clearly)  do
ou  feel  right  now?’  Response  was  by  visual  analog  scale
VAS)  from  0  (‘No  Fatigue’)  to  10  (‘Extreme  Fatigue’).  The
omentary  fatigue  item  reﬂected  both  the  physical  and
ental  fatigue  components  of  the  generally  accepted  deﬁ-
ition  of  MS  fatigue  as  ‘‘a  subjective  lack  of  physical  and/or
ental  energy. .  .’’ (Multiple  Sclerosis  Council  for  Clinical
ractice  Guidelines,  1998,  p.  2).  Convergent  and  discrimi-
ant  validity  were  demonstrated  by  negative  within-person
ssociations  with  concurrent  Energetic  (r  =  −.45)  and  Alert
r  =  −.44)  single-items,  and  weak  associations  with  both  Anx-
ous  (r  =  .09)  and  Distressed  (r  =  .13)  single-items.  Fatigue
eports  were  provided  in  91.1%  of  quasi-random  momentary
ssessments.
Upon  awakening  (S1),  participants  were  presented  with
tems  regarding  sleep  quality  (‘How  would  you  rate  your
leep  last  night?’  with  VAS  response  0  ‘Very  Bad’  to  10  ‘Very
ood’)  and  recalled  time  of  sleep  (‘What  time  did  you  go  to
leep  last  night?’  with  digital  clock  response).  Hours  slept
as  computed  as  the  time  elapsed  between  self-reported
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ime  of  sleep  and  time  of  S1.  Individual  items  were  also  pre-
ented  to  indicate  whether  participants  had  eaten  a  meal,
rank  coffee,  smoked,  exerted  physically,  or  slept  in  the
0  min  prior  to  the  prompt.
.5.  Statistical  procedures
tatistical  analysis  was  by  multilevel  modeling  (Snijders  and
osker,  2012) using  SPSS  Version  21.  The  criterion  for  statis-
ical  signiﬁcance  was  ˛  =  .05.  Each  multilevel  model  used  to
est  a  hypothesis  is  speciﬁed  in  the  supplementary  material
Appendix  A)  using  notation  from  Snijders  and  Bosker  (2012).
or  group  comparisons  using  cortisol  data,  and  in  addition
o  multilevel  analysis,  Cohen’s  d  effect  sizes  were  computed
rom  person-means  and  standard  deviations  using  indepen-
ent  samples  t-tests  to  facilitate  comparisons  with  existing
esearch.
Potential  covariates  were  added  to  each  model  in  a
tep-wise  manner  in  data-level  order:  (1)  assessment-
evel  (eating,  smoking,  caffeine,  being  at  work,  physical
xertion);  (2)  day  level  (sleep  quality,  time  of  awak-
ning,  morning  stress);  and  (3)  individual  level  (age,
ender,  menstrual  phase,  contraceptive  use,  DMT-use).  All
ssessment-level  and  day-level  covariates  were  centered  to
he  person-mean,  unless  binary.  The  criterion  for  retaining
ovariates  in  the  ﬁnal  model  was  ˛  =  .10.  Potential  outliers
ere  identiﬁed  using  a  mean  ±  3  SD  criterion  (Schlotz,  2012)
nd  were  excluded  in  sensitivity  analysis.  The  number  of  out-
iers  removed  in  each  sensitivity  analysis  is  declared  within
he  Results  section.
.5.1.  Testing  hypothesis  1
alid  CARs  were  deﬁned  as  comprising  an  S1  sample  provided
ithin  8  min  of  the  S1  auditory  prompt  or  manual  initia-
ion  (Smyth  et  al.,  2013),  and  S2  and  S3  samples  provided
ithin  37  min  and  52  min,  respectively,  of  the  S1  auditory
rompt  (Kudielka  et  al.,  2003).  Missing,  delayed,  or  ineligi-
le  or  incorrectly  labeled  S1—S3  samples  led  to  the  exclusion
f  that  day’s  CAR.  At  least  two  complete  CARs  from  the  4
ssessment  days  were  required  for  a  participant’s  data  to  be
etained.
Two-level  models  (days  nested  within  individuals)  were
uilt  for  each  of  the  three  CAR  outcomes:  AUCg,  AUCi,  and
1  cortisol.  A  natural  log-transformation  brought  the  S1  cor-
isol  data  closer  to  a  normal  distribution;  transformation  was
ot  required  for  AUCg  or  AUCi.  The  absence  of  a  cortisol
evel  rise  post-awakening  has  been  argued  to  potentially
ndicate  protocol  non-adherence  (Thorn  et  al.,  2006),  so
upplementary  responder-only  CAR  analyses  are  presented.
esponders  were  deﬁned  as  where  S2  or  S3  cortisol  level
as  >1.5  nmol/L  higher  than  S1  cortisol  level  on  a  given
ssessment  day  (Miller  et  al.,  2013).  Group  differences  were
etermined  by  a  binary  ﬁxed  effect  for  group.
The  DCS  was  computed  as  the  linear  slope  parameter
effect  of  time)  estimated  by  a  3-level  multilevel  model
assessments  nested  within  days  within  individuals)  of  log-
ransformed  cortisol  data  collected  at  S4—S9  assessments.
e  required  cortisol  samples  with  correct  codes  from  at
east  50%  (3  of  6)  of  S4—S9  assessments  to  retain  that  day’s
CS.  Group  differences  in  DCS  were  determined  by  the  group
y  time  interaction  effect.  HADS-Depression  subscale  scores
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Figure  1  Cortisol  awakening  response  represented  by  the
mean of  the  within-subject  means  for  samples  at  0  (S1),  30
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and  CSSS  scores  were  entered  into  each  model  as  ﬁxed
effects  to  adjust  the  model  for  depressive  symptoms  and
chronic  stress.
2.5.2.  Testing  hypothesis  2
To  test  the  association  of  fatigue  with  cortisol  secre-
tory  activity,  we  ran  the  hypothesis  1  models  with  FS
score  and  group  by  FS  score  interaction  entered  as  ﬁxed
effects.  Where  a  statistically  signiﬁcant  association  was
found  between  cortisol  (CAR  or  DCS)  and  fatigue,  sensitiv-
ity  analysis  was  conducted  whereby  models  were  adjusted
for  CSSS,  HADS-Depression  subscale,  EDSS-sa,  and  employ-
ment  status  scores.  In  supplementary  analyses,  the  RRMS
group  was  divided  into  those  with  (RRMS-f,  n  =  21)  and  with-
out  (RRMS-nf,  n  =  17)  clinically  signiﬁcant  fatigue  using  the
bimodal  FS  cut-off  (≥4).  For  group  comparisons,  speciﬁed
multilevel  models  for  CAR  outcomes  and  DCS  were  rerun
with  dummy  variables  representing  the  three  groups  (RRMS-
f,  RRMS-nf,  control)  as  binary  ﬁxed  effects  with  comparator
0.
2.5.3.  Testing  hypothesis  3
A  2-level  model  with  daily  fatigue  severity  as  outcome  was
built  to  test  whether  the  CAR  predicted  same-day  fatigue
severity  within-individuals.  Daily  fatigue  severity  was  opera-
tionalized  as  the  daily  mean  of  momentary  fatigue  ratings.
CAR  measures  and  group  by  CAR  interaction  terms  were
entered  into  consecutive  models  as  ﬁxed  effects.
3. Results
3.1.  Cortisol  awakening  responseThe  CAR  AUCg  and  AUCi  analyses  were  based  on  258
assessment  days  (84.8%)  nested  within  75  participants  (37
RRMS;  38  Control);  one  participant  provided  no  valid  CAR
d
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Table  2  Multilevel  parameters  estimates  of  group  differences  in  
Fixed  effect  Coefﬁcient  SE  
Model  for  CAR  AUCg
Intercept  11.831  0.543  
Group 1.715  0.767  
Model for  CAR  AUCi
Intercept  2.375  0.476  
Group −0.591  0.669  
Model for  (ln)  S1  cortisol
Intercept  2.267  0.058  
Group 0.149  0.082  
Model for  DCSa
Intercept  1.687  0.053  
Time −0.091  0.007  
Group 0.109  0.074  
Time*Group −0.005  0.010  
Note. CAR indicates cortisol awakening response; AUCg, area under the
upon awakening; DCS, diurnal cortisol slope. Data presented is from re
a Fixed effects of signiﬁcant covariates (recent meal, recent smokin
tor group (controls). Group ﬁxed effect parameters represent differen
parameter indicates a larger cortisol outcome). For Time*Group, a posS2), and  45  min  (S3)  post-awakening.  Error  bars  represent  the
tandard  error  of  the  mean.
ssessments  and  was  excluded.  S1  cortisol  analysis  was
ased  on  298  assessment  days  (98.0%)  nested  within  76
articipants.  Of  the  258  CARs  measured,  177  (68.6%)  were
lassiﬁed  as  responder  (RRMS,  69.7%;  Control,  67.5%).
The  CAR  proﬁles  for  the  RRMS  and  control  groups  are  pre-
ented  in  Fig.  1. As  shown  in  Table  2, a statistically  signiﬁcant
roup  difference  was  found  for  CAR  AUCg  such  that,  on  aver-
ge,  cortisol  output  in  the  CAR  period  was  1.72  nmol/L/min
reater  in  the  RRMS  group  than  the  control  group.  Removing
n  outlying  AUCg  assessment  from  the  dataset  did  not  sub-
tantially  affect  the  result,  p  =  .044,  95%  CI  [0.043,  3.00].
RMS  group  CARs  typically  showed  a  higher  S1  cortisol  level,
lbeit  not  to  statistical  signiﬁcance  (p  =  .074),  followed  by  an
wakening  response  (AUCi)  that  was  no  different  from  con-
rols.  In  responder-only  analysis,  the  group  difference  for
AR  AUCg  was  diminished,  p  =  .147,  95%  CI  [−0.407,  2.665].
able  3  presents  means  and  SDs  of  person-mean  CAR  data,
emonstrating  the  group  difference  in  AUCg  represented  a
edium  effect  size.
Although  the  group  difference  for  CAR  AUCg  was  some-
hat  diminished  in  a  model  adjusted  for  depressive
cortisol  secretory  activity.
t  p  95%  CI
21.772  <.001  [10.748,  12.912]
2.236  .028  [0.187,  3.242]
4.992  <.001  [1.431,  3.319]
−0.883  .379  [−1.919,  0.737]
38.947  <.001  [2.151,  2.383]
1.808  .074  [−0.015,  0.313]
32.107  <.001  [1.583,  1.792]
−12.826  <.001  [−0.105,  −0.076]
1.469  .146  [−0.039,  0.257]
−0.512  .610  [−0.025,  0.015]
 curve ground; AUCi, area under the curve increase; S1, cortisol
sponder and non-responder days.
g) not presented. Intercepts represent parameters for compara-
ce between RRMS group and comparator group (i.e., a positive
itive parameter indicates a ﬂatter DCS.
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Table  3  Mean  of  Person-Means  (SD)  for  Cortisol  Awakening  Response  outcomes  in  each  group.
CAR  RRMS  Control  t  p  95%  CI  d
AUCg  (nmol/L/min)  13.57  (3.77)  11.78  (2.95)  2.29  .03  [0.23,  3.35]  0.53
AUCi (nmol/L/min)  1.88  (3.22)  2.02  (2.69)  0.21  .84  [−1.51,  1.22]  −0.04
(ln) S1  2.41  (0.41)  2.28  (0.31)  1.49  .14  [−0.04,  0.29]  0.36
(ln) S2  2.71  (0.28)  2.60  (0.26)  1.74  .09  [−0.02,  0.23]  0.41
(ln) S3 2.56  (0.29) 2.46  (0.28)  1.42  .21  [−0.04,  0.23]  0.35
Note. CAR indicates cortisol awakening response; AUCg, area under the curve ground; AUCi, area under the curve increase; S1, cortisol
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rupon awakening; S2, cortisol 30 min after awakening; S3, cortiso
responder days. Signiﬁcance tests use independent samples t-test
ymptoms,    =  2.013,  SE  =  1.306,  p  =  .128,  95%  CI  [−0.590,
.616],  depressive  symptoms  were  not  associated  with
AR  AUCg  in  either  the  RRMS  group,    =  0.033,  SE  =  0.234,
 =  .887,  95%  CI  [−0.433,  0.500],  or  the  control  group,
 =  0.212,  SE  =  0.244,  p  =  .388,  95%  CI  [−0.274,  0.698].
.2.  Diurnal  cortisol  slope
he  DCS  analysis  was  based  on  1637  assessments  nested
ithin  296  days  within  76  individuals.  Group  comparisons
re  presented  within  Table  2  (ﬁtted  linear  regression  lines
or  each  participant  are  presented  in  Fig.  B.1  in  Appendix  B).
s  expected,  there  was  a  statistically  signiﬁcant  decreasing
rend  in  cortisol  levels  over  time  in  both  groups,  but  the  DCS
id  not  differ  between  groups.
.3.  Cortisol  and  fatigue
arameters  from  models  testing  associations  between  FS
core  and  different  facets  of  cortisol  secretion  in  the  two
roups  are  presented  in  Table  4.  In  the  RRMS  group,  CAR
UCg  was  not  associated  with  FS  score.  However,  S1  cortisol
as  negatively  associated  with  FS  score  in  the  RRMS  group,
uch  that  lower  cortisol  levels  were  associated  with  greater
atigue  (see  Fig.  B.2A  in  Appendix  B);  an  association  that
as  reﬂected  in  both  the  physical  and  mental  FS  subscales.
n  addition,  a  larger  CAR  AUCi  was  associated  with  higher  FS
core  in  the  RRMS  group,  such  that  those  with  greater  fatigue
ad  larger  rises  in  cortisol  post-awakening  (see  Fig.  B.2B  in
ppendix  B).  Similar  associations  with  CAR  AUCi  were  found
or  both  FS  subscales.  No  CAR  measure  was  associated  with
S  score  in  the  control  group.  The  DCS  was  not  associated
ith  FS  score  in  either  group.
Across  all  participants,  FS  score  was  associated  with
ADS-Depression  score  (r  =  .335,  p  =  .003)  and  CSSS  score
r  =  .228,  p  =  .047).  However,  cortisol-fatigue  associations  in
he  RRMS  group  remained  after  controlling  for  depressive
ymptoms  (HADS  Depression  score),  chronic  stress  (CSSS
core),  neurological  disability  (EDSS  score),  and  employment
ours.  For  both  S1  and  CAR  AUCi,  excluding  cortisol  out-
iers  (2  S1  outliers;  4  AUCi  outliers)  and  an  individual  who
eported  FS  =  1  did  not  substantially  affect  any  association
ith  FS  score..3.1.  Clinically  signiﬁcant  fatigue
he  RRMS  group  was  divided  into  fatigued  (RRMS-f,
 =  21)  and  non-fatigued  (RRMS-nf,  n  =  16)  subgroups
3
N
fin  after awakening. Data presented is from responder and non-
ased  on  the  standard  cut-off  on  the  FS.  There  were
o  statistically  signiﬁcant  subgroup  differences  for  age,
ender,  paid  employment,  or  awakening  time  (ps  >  .270).
elf-reported  levels  of  sleep  quality  were  similar  in  the
RMS-f  and  RRMS-nf  subgroups  (MRRMS-f =  5.937,  SD  =  1.812;
RRMS-nf =  6.245,  SD  =  1.232,  U  =  168.500,  p  =  .769),  as
ere  HADS-Depression  scores  (MRRMS-f =  4.428,  SD  =  2.158;
RRMS-nf =  3.471,  SD  =  2.401,  U  =  136.500,  p  =  .213)  and
SSS  scores  (MRRMS-f =  20.952,  SD  =  9.573;  MRRMS-nf =  18.412,
D  =  9.172,  t  =  −0.829,  p  =  .413).  However,  the  RRMS-f
ubgroup  was  somewhat  more  disabled  than  the  RRMS-
f  subgroup  (MRRMS-f =  4.691,  SD  =  0.887;  MRRMS-nf =  3.794,
D  =  1.705,  U  =  114.500,  Z  =  1.912,  p  =  .056).
Compared  to  the  control  group,  CAR  AUCg  was  ele-
ated  only  in  the  RRMS-nf  subgroup,    =  2.170,  SE  =  0.951,
 =  2.281,  p  = .025,  95%  CI  [0.275,  4.064],  and  not  the  RRMS-
 subgroup,    =  1.032,  SE  =  0.864,  t  =  1.193,  p  =  .237,  95%  CI
−0.691,  2.754].  There  was  no  statistically  signiﬁcant  dif-
erence  between  RRMS  subgroups  for  CAR  AUCg,    =  1.138,
E  =  1.053,  t  =  1.081,  p  =  .283,  95%  CI  [−0.960,  3.237].  S1
ortisol  levels  were  higher  in  the  RRMS-nf  subgroup  com-
ared  to  both  the  control  group,    =  0.274,  SE  =  0.102,
 =  2.696,  p  =  .009,  95%  CI  [0.072,  0.478],  and  the  RRMS-f
ubgroup,    =  0.228,  SE  =  0.114,  t  =  2.003,  p  =  .049,  95%  CI
0.001,  0.456].  The  difference  in  CAR  AUCi  between  RRMS-
 and  RRMS-nf  subgroups  did  not  quite  reach  statistical
igniﬁcance,    =  1.686,  SE  =  0.854,  t  =  1.973,  p  =  .052,  95%
I  [−0.012,  3.384],  while  we  detected  no  difference  in
AR  AUCi  between  RRMS-f  and  controls,    =  0.574,  t  =  0.822,
E  =  0.698,  p  =  .413,  95%  CI  [−0.814,  1.961],  or  RRMS-nf  and
ontrols,    =  −1.112,  SE  =  0.776,  t  =  −1.432,  p  =  .156,  95%  CI
−2.655,  0.431].  Mean  CAR  proﬁles  for  each  subgroup  are
resented  in  Fig.  2.
There  was  no  difference  in  DCS  between  subgroups,
ut  cortisol  levels  were  elevated  in  the  RRMS-nf  group  at
000  h  compared  to  the  control  group,    =  0.192,  SE  =  0.094,
 =  2.047,  p  =  .044,  95%  CI  [0.005,  0.378].  RRMS-f  vs  Control
nd  RRMS-f  vs  RRMS-nf  subgroup  comparisons  at  1000  h  were
ot  statistically  signiﬁcant.  Therefore,  despite  cortisol  lev-
ls  being  similar  at  S3  for  all  RRMS-f  and  RRMS-nf  subgroups,
ortisol  level  decreased  more  slowly  between  45  min  after
wakening  and  1000  h  in  the  RRMS-nf  subgroup.  This  effect
emained  after  controlling  for  awakening  time..3.2.  Within-person  analysis
o  associations  between  facets  of  the  CAR  and  same-day
atigue  severity  were  statistically  signiﬁcant  in  either  group.
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Table  4  Multilevel  parameter  estimates  of  associations  between  Fatigue  Scale  score  and  cortisol  secretory  activity  in  the  RRMS
group and  control  group.
RRMS  Control
Fixed  effect  Coef.  SE  t  p  95%  CI  Coef.  SE  t  p  95%  CI
Model  for  CAR  AUCg
FS Score −0.089  0.076  −1.168  .246  [−0.241,  0.063]  0.017  0.189  0.090  .928  [−0.360,  0.394]
Models for  CAR  AUCi
FS  Score 0.157 0.064 2.442 .017 [0.029,  0.285]  0.087  0.160  0.543  .588  [−0.231,  0.405]
FS Physical 0.216 0.093 2.316 .023 [0.031,  0.400] 0.094 0.194 0.482  .631  [−0.292,  0.480]
FS Mental  0.391  0.175  2.235  .028  [0.044,  0.739]  0.219  0.502  0.324  .663  [−0.776,  1.214]
Models for  (ln)  S1  cortisol
FS Score  −0.022  0.008  −2.781  .007  [−0.038,  −0.006]  −0.008  0.019  −0.387  .700  [−0.046,  0.031]
FS Physical  −0.028  0.012  −2.454  .016  [−0.051,  −0.005]  −0.009  0.024  −0.393  .695  [−0.058,  0.039]
FS Mental  −0.060  0.021  −2.865  .005  [−0.102,  −0.018]  −0.011  0.059  −0.191  .849  [−0.129,  0.106]
Model for  DCS
Time*FS  Score  0.0010  0.0010  1.038  .302  [−0.0009,  0.0030]  0.0045  0.0024  1.847  .069  [−0.0004,  0.0093]
Note. CAR indicates cortisol awakening response; AUCg, area under the curve ground; AUCi, area under the curve increase; S1, cortisol
upon awakening; DCS, diurnal cortisol slope. Data presented is from re
Figure  2  Cortisol  awakening  response  represented  by  the
mean of  the  within-subject  means  for  samples  at  0  (S1),  30
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s(S2), and  45  min  (S3)  post-awakening.  Error  bars  represent  the
standard  error  of  the  mean.
In  the  RRMS  group,  CAR  AUCg,  p  =  .814,  95%  CI  [−0.062,
0.079],  S1  cortisol,  p  =  .625  95%  CI  [−0.776,  0.467],  and
CAR  AUCi,  p  =  .911,  95%  CI  [−0.067,  0.075],  were  not  asso-
ciated  with  same-day  fatigue  severity.  In  the  control  group,
an  association  between  greater  CAR  AUCg  and  higher  same-
day  fatigue  was  close  to  statistical  signiﬁcance,    =  0.081,
SE  =  0.042,  t  =  1.942,  p  =  .054,  95%  CI  [−0.001,  0.164],  but
neither  S1  cortisol,  p  =  .496,  95%  CI  [−0.460,  0.946]  nor  CAR
AUCi,  p  =  .895,  95%  CI  [−0.078,  0.068]  was  associated  with
fatigue  within  individuals.
4. Discussion
The  present  study  provided  some  support  for  our  ﬁrst
hypothesis  that  the  CAR  is  larger  in  people  with  RRMS
than  healthy  individuals,  although  this  difference  was  only
apparent  for  cortisol  output  (CAR  AUCg)  and  not  the
post-awakening  cortisol  increase  (CAR  AUCi).  Diurnal  cor-
tisol  slopes  were  similar  across  groups.  Group  differences
remained  after  adjusting  for  severity  of  neurological  and
depressive  symptoms,  and  chronic  stress.  Although  total  cor-
tisol  output  was  associated  with  RRMS,  this  did  not  appear  to
s
w
a
tsponder and non-responder days.
xplain  the  fatigue  experienced  by  many  with  RRMS.  RRMS
atigue  was  associated  with  a low  waking  (S1)  cortisol  level
nd  greater  post-awakening  cortisol  increases  (AUCi),  rather
han  cortisol  output  (AUCg).  There  was  no  support  for  the
nal  hypothesis  in  either  group:  daily  CARs  did  not  predict
ame-day  fatigue  ratings  within  individuals.
Our  data  showing  that  cortisol  output  in  the  CAR  is
levated  in  RRMS  compared  to  healthy  controls  supports
revious  case—control  studies  with  CAR  comparisons  (Kern
t  al.,  2011,  2013).  Our  ﬁndings  add  to  other  studies  using
 variety  of  methods  that  have  reported  hyperactivity  in
ome  facet  of  basal  cortisol  secretion  in  RRMS  (Ysrraelit
t  al.,  2008;  Gold  et  al.,  2010;  Kern  et  al.,  2011,  2013;
elief  et  al.,  2013).  However,  our  data  contests  the  hypothe-
is  that  comorbid  depression  drives  cortisol  hyper-secretion
n  RRMS  (Gold  et  al.,  2010,  2011;  Kern  et  al.,  2011);  we
emonstrated  heightened  CAR  output  in  individuals  with
RMS  who  did  not  have  comorbid  major  depressive  disor-
er  and  had  relatively  mild  levels  of  depressive  symptoms.
n  other  studies,  depression  in  MS  was  not  associated  with
4  h  urinary  cortisol  (Ysrraelit  et  al.,  2008),  cerebrospinal
uid  cortisol  (Melief  et  al.,  2013),  or  salivary  cortisol  in  a  2-
ay  study  (Kern  et  al.,  2013).  Of  course,  results  we  present
o  not  rule  out  major  depressive  disorder  further  exagger-
ting  HPA  axis  hyperactivity  in  RRMS  beyond  that  driven  by
RMS-speciﬁc  disease  processes.  Like  Kern  et  al.  (2013),  we
ound  no  evidence  that  neurological  disability  was  impli-
ated  in  salivary  cortisol  outcomes  and  agree  that  this  likely
oints  to  the  present  disease  state,  rather  than  accumu-
ated  deﬁcits,  being  responsible  for  changes  in  HPA  axis
ctivity.
Our  data  suggest  greater  cortisol  output  within  the  CAR  in
RMS  is  characterized  by  a  larger  pre-awakening  rise  in  cor-
isol  levels  followed  by  a  post-awakening  rise  that  is  broadly
imilar  to  that  of  healthy  individuals.  The  CAR  proﬁles  pre-
ented  by  Kern  et  al.  (2013)  seem  to  follow  a  similar  pattern,
ith  cortisol  levels  already  higher  in  the  RRMS  group  upon
wakening  followed  by  a  post-awakening  rise  similar  in  size
o  controls.
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Pre-awakening  HPA  axis  activity  is  thought  to  consist  of
 period  of  dissociation  between  ACTH  and  cortisol  secre-
ion  (Clow  et  al.,  2010)  evidenced  by  ACTH  levels  increasing
ore  quickly  than  cortisol  pre-awakening  (Wilhelm  et  al.,
007).  This  pre-awakening  dissociation  may  be  attributable
o  enhanced  inhibitory  actions  by  the  hippocampus  while
apid  eye  movement  sleep  is  dominant  and  hippocampal
ctivity  is  increased  (Clow  et  al.,  2010).  Several  studies  have
eported  that  smaller  hippocampal  volume  or  hippocampal
amage  is  associated  with  higher  S1  cortisol  levels  (Frodl
nd  O’Keane,  2013)  and  studies  have  demonstrated  smaller
ippocampal  regions  in  RRMS  (Sicotte  et  al.,  2008;  Gold
t  al.,  2010).  We  speculate  that  the  heightened  CAR  output
n  RRMS  reported  in  the  present  study  could  be  attributed
o  a  reduction  in  the  expected  ACTH-cortisol  dissociation
rior  to  awakening  due  to  impaired  hippocampal  function-
ng  in  RRMS.  Flatter  DCS  has  previously  been  associated  with
 smaller  CA23DG  hippocampal  region  volume  in  RRMS  (Gold
t  al.,  2010).
Bearing  in  mind  average  CAR  output  (AUCg)  and  fatigue
ere  greater  in  the  RRMS  group  when  compared  to  con-
rols,  and  the  post-awakening  rise  (AUCi)  was  broadly  similar
cross  group,  it  may  seem  surprising  to  ﬁnd  no  association
etween  RRMS  fatigue  severity  and  CAR  output,  and  yet  a
ositive  association  with  fatigue  and  the  post-awakening
ise.  The  lack  of  a  relationship  between  fatigue  and  over-
ll  cortisol  output  is  in  line  with  a  systematic  review  we
reviously  conducted  on  cortisol  secretory  activity  and
atigue  in  physical  health  conditions  (Powell  et  al.,  2013).
owever,  the  systematic  review  found  attenuated  diurnal
ortisol  variability  (e.g.,  reduced  post-awakening  increase)
as  most  relevant  to  fatigue  across  populations;  we  have
ound  a  contrary  positive  association  in  the  RRMS  group  in
he  present  study.  Of  note,  the  only  study  of  a  clinical  pop-
lation  included  in  the  systematic  review  that  reported  a
ositive  association  between  the  post-awakening  cortisol
ise  and  fatigue  severity  was  in  rheumatoid  arthritis  (Dekkers
t  al.,  2000).  With  rheumatoid  arthritis  being,  like  MS,  an
utoimmune  disease  characterized  by  high  levels  of  inﬂam-
ation,  there  may  be  different  mechanisms  of  fatigue  in
nﬂammatory  autoimmune  disease  vs  fatigue  in  other  clini-
al  groups.
Cortisol  is  known  to  be  an  important  endogenous
egulator  of  inﬂammation  (Chrousos,  1995),  and  stud-
es  have  shown  concurrently  high  levels  of  cortisol  and
ro-inﬂammatory  cytokines  in  MS  (e.g.,  Ysrraelit  et  al.,
008).  Speculatively,  MS-related  fatigue  may  manifest  in
he  absence  of  sufﬁcient  down-regulation  of  inﬂammation
y  cortisol,  particularly  in  the  mornings.  This  suggestion  is
upported  by  our  ﬁnding  that  average  cortisol  levels  were
till  elevated  at  1000  h  in  the  RRMS  not-fatigued  subgroup.
uture  research  into  the  mechanisms  underlying  associations
etween  cortisol  dysregulation  and  fatigue  in  MS  should  seek
o  simultaneously  examine  both  cortisol  and  inﬂammatory
arkers  and  their  association  with  MS-related  fatigue  in  a
ongitudinal  design.
Within  individuals,  we  found  no  association  between  day-
o-day  changes  in  the  CAR  and  same-day  fatigue  severity
n  RRMS.  This  ﬁnding  differs  from  negative  associations
eported  between  the  CAR  and  same-day  symptoms  in  clin-
cal  burnout  (Sonnenschein  et  al.,  2007)  and  same-day
hysical  symptoms  in  general  population  samples  (Adam
t
d
dD.J.H.  Powell  et  al.
t  al.,  2006;  Gartland  et  al.,  2014).  The  fact  we  found  no
ssociation  between  the  CAR  and  same-day  fatigue  in  RRMS
ight  suggest  that  day-to-day  variability  in  MS  fatigue  is
elated  to  psychosocial  and  contextual  factors  in  daily  life,
hich  may  include  perceived  demand  and  sleep  quality.  A
road  range  of  psychological  factors  have  previously  been
hown  to  correlate  with  recalled  fatigue  in  MS  (Bol  et  al.,
009),  while  interventions  based  on  a  cognitive  behavioral
odel  of  MS  fatigue  (van  Kessel  and  Moss-Morris,  2006)  have
een  shown  to  successfully  reduce  fatigue  in  MS  (van  Kessel
t  al.,  2008).  The  role  of  psychosocial  factors  in  account-
ng  for  fatigue  variability  within  people  with  MS  warrants
urther  investigation,  particularly  as  these  factors  may  be
menable  to  change.
Importantly,  MS  fatigue  appears  a  highly  complex  phe-
omenon  of  multifactorial  origin  with  variability  not  only
etween  individuals  but  also  within  individuals.  Previ-
us  studies  have  indicated  positive  associations  between
S  fatigue  and  pro-inﬂammatory  cytokines  (Flachenecker
t  al.,  2004;  Heesen  et  al.,  2006),  brain  lesion  load  (Colombo
t  al.,  2000;  Tedeschi  et  al.,  2007),  psychosocial  stress
Trojan  et  al.,  2007),  and  various  associations  with  cogni-
ive  and  behavioral  factors  (Skerrett  and  Moss-Morris,  2006).
owever,  evidence  is  frequently  mixed;  for  example,  MS
atigue  has  been  associated  with  smaller  lesion  loads  in
nother  study  (Codella  et  al.,  2002).  Several  reviews  have
ow  been  written  describing  current  understanding  of  the
ultifactorial  origins  of  MS  fatigue  (see  Kos  et  al.,  2008;
rupp  et  al.,  2010;  Induruwa  et  al.,  2012).
The  present  study  has  a  number  of  methodological
trengths  to  highlight.  First,  all  participants  were  clini-
ally  stable  (remission-phase)  with  sufﬁcient  recovery  time
>3  months)  from  relapse  and  associated  corticosteroid
reatments,  and  had  no  other  comorbidity.  These  eligibil-
ty  criteria  contributed  toward  a  relatively  homogeneous
RMS  sample,  which  increased  our  conﬁdence  in  attribut-
ng  ﬁndings  to  RRMS  and  to  MS-related  fatigue  rather  than
n  extraneous  factor.  We  acknowledge  this  necessarily  limits
he  generalizability  of  the  ﬁndings.
The  cortisol  sampling  protocol  was  the  most  comprehen-
ive  to  date  in  an  MS  population:  nine  saliva  samples  over
 weekdays  provided  greater  measurement  reliability  and
ower  to  detect  effects  than  has  been  achieved  in  previ-
us  2-day  protocols  (Gold  et  al.,  2010,  2011;  Kern  et  al.,
011,  2013).  Sampling  over  consecutive  days  limited  the
pportunity  to  self-select  assessment  days.  Despite  these
ethodological  improvements,  it  should  be  noted  that  it
as  been  suggested  that  6  days’  and  10  days’  sampling  may
e  required  to  adequately  examine  between-person  associa-
ions  with  the  CAR  AUCi  and  DCS,  respectively  (Hellhammer
t  al.,  2007;  Segerstrom  et  al.,  2014).  Many  steps  were
aken  to  maximize  compliance  with  the  sampling  protocol  in
aily  life,  including  using  audible  prompts  and  random  code
eneration.  We  report  excellent  rates  of  compliance.  How-
ver,  future  studies  may  also  use  mobile  polysomnography
r  actigraphy  to  objectively  validate  time  of  awakening
nd  promptness  of  S1  saliva.  Although  all  participants  were
riefed  to  engage  with  their  handheld  upon  awakening  and
o  pre-set  the  S1  waking  alarm,  it  was  impossible  to  be
eﬁnitively  certain  this  occurred  for  all  sampling  days.
There  are  other  limitations  to  acknowledge.  Firstly,  we
id  not  directly  assess  MS  patients  for  sleep  disorders.
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Although  we  excluded  participants  with  multimorbidity  dur-
ing  recruitment,  sleep  disorders  are  underdiagnosed  in  MS
(Brass  et  al.,  2014).  Sleep  disorders,  such  as  restless  leg  syn-
drome,  periodic  leg  movement  disorder,  and  sleep  apnea
are  all  relatively  common  in  MS  (Marrie  et  al.,  2014)  and
are  associated  with  increased  fatigue  (Veauthier  and  Paul,
2014).  However,  we  report  similar  ratings  of  sleep  quality
across  groups,  so  believe  it  is  unlikely  that  sleep  disorders
have  had  a  biasing  effect  on  our  results.  Secondly,  although
we  did  investigate  DMT-use  as  a  potential  covariate  in  anal-
yses,  we  could  not  include  speciﬁc  DMTs  as  covariates  due  to
limited  numbers.  Interferon  has  an  inﬂuenza-like  side  effect
in  around  half  of  MS  patients  (Filippini  et  al.,  2003) which
may  have  affected  fatigue  symptoms,  but  we  found  similar
FS  scores  for  those  taking  interferon  and  those  who  were  not
(p  =  .832).  In  addition,  a  large  cross-sectional  study  found
no  differences  in  fatigue  ratings  between  MS  patients  tak-
ing  immunosuppressant  or  immunomodulatory  medications
and  MS  patients  who  were  treatment-free  (Putzki  et  al.,
2008).
In  summary,  we  have  demonstrated  greater  CAR  output
in  RRMS,  independent  of  depression.  We  found  associations
of  low  waking  cortisol  (pre-awakening  rise)  and  greater
post-awakening  cortisol  rises  with  higher  ratings  of  recalled
fatigue  severity  in  RRMS.  These  associations  were  indepen-
dent  of  depressive  symptoms  and  stress,  both  factors  that
are  related  to  fatigue  in  MS  (Trojan  et  al.,  2007).  In  people
with  RRMS,  there  was  no  within-person  association  between
the  CAR  and  same-day  fatigue.  Cortisol  secretory  activity
appears  to  be  implicated  in  fatigue  experience  in  RRMS,  but
whether  it  is  a  causal  factor  remains  unclear.
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